45 results about "Equine influenza virus" patented technology

The present invention relates to providing new vaccines and treatments for the diseases related to canine influenza virus. It discloses influenza viral antigens, and methods of presenting these antigens to canines, especially dogs. It relates to attenuated and killed vaccines. The present invention relates to experimentally generated canine and equine influenza viruses. The invention also includes influenza A, including H3, N8, H3N8, H7N7 and viruses which contain at least one genome segment from an canine or equine influenza virus. The present invention also relates to the use of these viruses in therapeutic compositions to protect canines, dogs in particular, from diseases caused by influenza viruses.

The invention provides an isolated H3 equine influenza A virus, as well as methods of preparing and using the virus, and genes or proteins thereof.

This invention relates to apparatus and methods of delivering various compositions including medicaments to a variety of targets. The invention includes a dose administrator (1) which may be used for intranasal delivery of compositions or medicaments, such as live virus vaccines, to both humans and animals. An axial collapse prevention element (2) to prevent excessive axial deflection of the dose administrator (1) or a dose-location coordinate indicator (3) to facilitate the delivery of a dose to the desired target location may be coupled to the dose administrator (1). An intranasal probe (4) having a force dissemination contact surface (7) may be responsive to a first end of the dose administrator (1). The dose may be delivered from a conformable dose sequestration element (10) through an aperture which penetrates the dose delivery aperture element (5) and the dose may be caused to stream by coupling a stream delivery element (6) to the dose delivery aperture element (5). The force application element (12) which acts upon the dose may be separated from the dose by a fluid dose propellent (13). While the invention may be used for numerous applications, it specifically addresses the difficulties of delivering cold-adapted live equine influenza viruses intranasally to equids.

The invention discloses a production method for vaccines of avian influenza virus and other influenza virus such as swine influenza, dog influenza and equine influenza, which comprises the following steps of: (1) transfer of culture and cultivation of vaccine-made cells; (2) reproduction of vaccine-made virus seeds; (3) microcarrier suspension culture of MDCK cells in a bioreactor; (4) reproduction of vaccine-made virus liquid; and (5) harvest of the virus liquid. The production method has the advantages of reducing the production cost greatly and improving the yield and quality of the vaccines obviously, along with short production period, no restriction to raw material supply, small occupied area, easy and quick expansion of production scale, light environmental pollution, easy processing, high automaticity, low employment and easy realization of balanced and stable quality.

Compositions, including vaccine compositions, and methods for treating, preventing or ameliorating canine influenza virus (CIV) disease by utilizing one or more canine influenza virus (CIV) or equine influenza virus (EIV) strain or immunogens thereof are set forth herein. Also set forth are challenge models useful in assessing the efficacy of a composition against canine influenza virus, comprising an equine influenza virus (EIV) or canine influenza virus (CIV) strain or immunogens thereof.

The invention discloses a method for diagnosticating an EIV and evaluating a multiple RT-PCR of the EIV subtype. The method comprises the following steps that: a RNA of a sample to be detected is taken as a template, two groups of ribonucleotide sequences of SEQ ID NO:1 and SEQ ID NO:2 as well as SEQ ID NO:3 and SEQ ID NO:4 are taken as primers to perform the RT-PCR reaction; if only the product of 227bp is amplified in the sample, the sample is H7N7 subtype of the EIV; if the products of both 227bp and 595bp are amplified simultaneously, the sample is H3N3 subtype of the EIV; if the product of 227bp is not amplified, the sample does not contain the EIV. According to the RT-PCR technical theory, the multiple RT-PCR detection method is established according to the characteristic that the EIV only has two HA subtypes. The method has strong sensitivity and high specificity and can be applied to the rapid diagnosis and the subtype verification of the EIV.

The invention discloses an H3N8 subtype equine influenza recombinant virus-like particle vaccine as well as a preparation method and an application thereof. The vaccine in the invention contains recombinant virus-like particle protein which is obtained by expressing nucleotide sequences as shown in SEQ ID NO.1 and SEQ ID NO.2 through an insect/baculovirus expression system, a pharmaceutically acceptable carrier, an adjuvant or an excipient. The recombinant virus-like particle has a morphological structure similar with that of a natural virus particle, and has good immunogenicity; the vaccine prepared by the recombinant virus-like particle can induce a mouse to generate good protective immune response after immunizing the mouse, and is free of any risk of live virus; and meanwhile, naturally infected persons and immune persons can be distinguished, so that epidemiological investigation is not affected, and therefore, the H3N8 subtype equine influenza recombinant virus-like particle vaccine disclosed by the invention can be used as a candidate vaccine for preventing and treating the equine influenza.

The invention discloses an efficient bidirectional transcription/expression plasmid and application thereof in influenza virus reverse genetics. The bidirectional transcription/expression plasmid is obtained by transformation by taking a eukaryotic expression vector pEF4/myc-His B as a skeleton. In order to create a reverse genetic system of EIVs (Equine influenza viruses), the bidirectional transcription/expression plasmid obtained by structuring is used for respectively expressing EIVs PB2, PB1, PA, HA, NP, NA and NS and M genes, and a strain of the EIV and mutants thereof are successfully saved by means of cotransfection, sequencing, drawing of growth curves and enzyme digestion are obtained. Compared with existing pBD systems, the created reverse genetic system is superior to the pBD systems in toxigenic quantity. A novel technical means is provided for research on reverse genetics of the influenza viruses, and a solid foundation is laid for future in-depth study on transmission of the EIVs, pathogenesis and even screening of vaccine candidates.

The invention discloses an anti-H3N8 subtype equine influenza virus monoclonal antibody and an application thereof. The anti-H3N8 subtype equine influenza virus monoclonal antibody is secreted by hybridoma cell strains with the microbial collection number of CGMCC No.3543. EL1SA, and Western-bolt methods prove that the monoclonal antibody of the invention has no cross reaction with equine infectious anemia virus, equine arteritis virus and normal chick embryo allantois fluid; and the abdominal dropsy ELISA valence of the H3N8/10 of the invention is 1:1.6*104. The anti-H3N8 subtype equine influenza virus monoclonal antibody of the invention can be applied to antigenicity analysis on A-type equine influenza virus, serodiagnosis, vaccine quality monitoring, epidemiological survey and other aspects.

The invention belongs to the technical field of medical biology, and relates to a codon-optimized H3HA/XJ3-07 gene and a nucleic acid vaccine thereof. In the invention, according to an HA protein sequence of an equine A-type influenza virus A/Equine/Xinjiang/3/07 (H3N8), an H3HA/XJ3-07 gene segment which can express a corresponding protein is chemically synthesized after codon optimization, and the segment is cloned into a nucleic acid vaccine vector pJW4303 to construct an equine influenza H3HA nucleic acid vaccine; and further, HA genes are modified, an H3-XJ HA natural signal peptide is replaced by a human tPA signal peptide or the gene segments of part of the HA genes are removed to make the HA genes only express an extracellular domain of the HA protein. The experimental result shows that three H3HA nucleic acid vaccines can be expressed in a 293T cell with high efficiency, and can induce the generation of specific anti-H3HA antibodies in New Zealand white rabbits.

This invention relates to apparatus and methods of delivering various compositions including medicaments to a variety of targets. The invention includes a dose administrator (1) which may be used for intranasal delivery of compositions or medicaments, such as live virus vaccines, to both humans and animals. An axial collapse prevention element (2) to prevent excessive axial deflection of the dose administrator (1) or a dose-location coordinate indicator (3) to facilitate the delivery of a dose to the desired target location may be coupled to the dose administrator (1). An intranasal probe (4) having a force dissemination contact surface (7) may be responsive to a first end of the dose administrator (1). The dose may be delivered from a conformable dose sequestration element (10) through an aperture which penetrates the dose delivery aperture element (5) and the dose may be caused to stream by coupling a stream delivery element (6) to the dose delivery aperture element (5). The force application element (12) which acts upon the dose may be separated from the dose by a fluid dose propellent (13). While the invention may be used for numerous applications, it specifically addresses the difficulties of delivering cold-adapted live equine influenza viruses intranasally to equids.

The invention is for a DNA vaccine expressing the hemagglutinin (HA1) gene of equine-2 influenza virus. By engineering a stop codon within HA1, expression of HA1 is ensured. By encapsulation of the DNA vaccine in liposome and by intranasal inoculation, it is sufficient to elicit protective immunity at a significantly lower dosage compared to a DNA vaccine expressing the full length HA gene. Lower dosage reduces the risk of induction of anti-DNA antibodies. Intranasal inoculation directly to the respiratory epithelial cells reduces the risk of DNA integration. The inventive vaccine is advantageous over current inactivated or live attenuated vaccines, as updating of the vaccine requires only the replacement of the encoding sequence with the new virus.

The invention provides a molecular beacon probe and a kit for detecting equine influenza virus pathogens. The molecular beacon probe and the kit belong to the field of biotechnology. The kit comprisesa primer pair for detecting a PB1-D sequence of H3N8 and a molecular beacon probe, nucleotide sequence of upstream primer of primer pair is SEQ: 1; wherein the nucleotide sequence of the forward primer is SEQ: 1, the nucleotide sequence of the reverse primer is SEQ: 2, the nucleotide sequence of the molecular beacon probe is SEQ: 3, the 5'end of the molecular beacon probe is subjected to fluorescence labeling with 5 (6)-carboxyl fluorescein (FAM), and the 3 'end of the molecular beacon probe is subjected to fluorescence labeling with quenched fluorescence 4-(4'-oxane aminobenzene azo) benzoicacid (DABCYL). The kit can inhibit generation of fluorescence signals caused by non-specific binding of the molecular beacon probe and reduce the signal-to-background ratio, so that detection signalscan accurately reflect the number of templates, and the specificity, sensitivity, repeatability and accuracy of detection are improved.

The present invention provides vaccine or immunogenic compositions comprising novel antigens derived from the equine strain of influenza H3N8. These proteins and specific immunogenic domains are effective as primary universal influenza antigens. The disclosed vaccines or immunogenic compositions are highly effective in inducing HA specific antibodies reactive to different influenza viruses, mucosal and systemic immune responses, and cross-protection regardless of influenza virus subtypes. In some embodiments, the vaccine is cross-protective against two or more (e.g., 2, 3, 4, 5, or 6) subtypes of influenza with or without the use of an adjuvant.